0 companies available
↑ ↓ to navigate Enter to select Esc to close
ABBOTT LABORATORIES
ABT
Pharmaceutical Preparations Last filing · Quarter 2 · Jun 30, 2026Export XLSX
Format
% Change
Rows
| USD ($) $ in Millions, shares in Millions | LTM | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Sales | - | $ 44,328 | $ 41,950 | $ 40,109 | ||||||||||||||
Cost of products sold, excluding amortization of intangible assets | - | 19,319 | 18,706 | 17,975 | ||||||||||||||
Amortization of intangible assets | - | 1,682 | 1,878 | 1,966 | ||||||||||||||
Research and development | - | 2,942 | 2,844 | 2,741 | ||||||||||||||
Acquired in-process and collaborations research and development | - | - | - | - | ||||||||||||||
Acquired in-process research and development | - | - | - | - | ||||||||||||||
Selling, general and administrative | - | 12,332 | 11,697 | 10,949 | ||||||||||||||
Total Operating Cost and Expenses | - | 36,275 | 35,125 | 33,631 | ||||||||||||||
Operating Earnings | - | 8,053 | 6,825 | 6,478 | ||||||||||||||
Interest expense | - | (493) | (559) | (637) | ||||||||||||||
Interest income | - | 308 | 344 | 385 | ||||||||||||||
Net foreign exchange (gain) loss | - | 50 | 27 | (41) | ||||||||||||||
Debt extinguishment costs | - | - | - | - | ||||||||||||||
Other (income) expense, net | - | 548 | 376 | 479 | ||||||||||||||
Earnings before Taxes | - | 8,466 | 7,013 | 6,664 | ||||||||||||||
Taxes on Earnings | - | 1,942 | (6,389) | 941 | ||||||||||||||
Earnings from Continuing Operations | - | - | - | - | ||||||||||||||
Earnings from Discontinued Operations, net of taxes | - | - | - | - | ||||||||||||||
Earnings from Discontinued Operations, net of taxes | - | - | - | - | ||||||||||||||
Gain on sale of Discontinued Operations, net of taxes | - | - | - | - | ||||||||||||||
Net Earnings from Discontinued Operations, net of taxes | - | - | - | - | ||||||||||||||
Net Earnings | $ 5,425 | $ 6,524 | $ 13,402 | $ 5,723 | ||||||||||||||
Basic Earnings Per Common Share -- | ||||||||||||||||||
Continuing Operations (in dollars per share) | - | - | - | - | ||||||||||||||
Discontinued Operations (in dollars per share) | - | - | - | - | ||||||||||||||
Basic Earnings Per Common Share (in dollars per share) | - | 3.73 | 7.67 | 3.28 | ||||||||||||||
Diluted Earnings Per Common Share -- | ||||||||||||||||||
Continuing Operations (in dollars per share) | - | - | - | - | ||||||||||||||
Discontinued Operations (in dollars per share) | - | - | - | - | ||||||||||||||
Diluted Earnings Per Common Share (in dollars per share) | - | $ 3.72 | $ 7.64 | $ 3.26 | ||||||||||||||
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) | - | 1,741 | 1,740 | 1,740 | ||||||||||||||
Dilutive Common Stock Options (in shares) | - | 7 | 8 | 9 | ||||||||||||||
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares) | - | 1,748 | 1,748 | 1,749 | ||||||||||||||
Outstanding Common Stock Options Having No Dilutive Effect (in shares) | - | 1 | 7 | 5 |